Quick Answer
Inhibitor Therapeutics, Inc. reported Operating Income of -$3.43 million for fiscal year 2025.
Inhibitor Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$3.43M | +6.3% |
| 2024 | -$3.66M | -7.4% |
| 2023 | -$3.40M | -417.5% |
| 2022 | -$657.9K | -102.2% |
| 2021 | -$325.4K | +69.3% |
| 2020 | -$1.06M | +61.5% |
| 2019 | -$2.75M | +39.8% |
| 2018 | -$4.56M | +10.8% |
| 2017 | -$5.12M | +27.1% |
| 2016 | -$7.02M | -77.8% |
| 2015 | -$3.95M | -0.3% |
| 2014 | -$3.94M | -96.9% |
| 2013 | -$2.00M | -256.7% |
| 2012 | -$560.7K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$741.2K | +8.9% | -6.5% |
| June 30, 2025 | -$695.8K | -18.9% | -3.1% |
| March 31, 2025 | -$674.6K | +12.9% | +17.0% |
| September 30, 2024 | -$813.2K | -7.1% | -39.0% |
| June 30, 2024 | -$585.1K | +21.2% | +24.5% |
| March 31, 2024 | -$774.8K | -23.0% | -2.0% |
| September 30, 2023 | -$759.5K | -985.2% | -2.3% |
| June 30, 2023 | -$742.5K | -948.6% | -17.9% |
- Inhibitor Therapeutics, Inc. showed an increase of +6.3% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Inhibitor Therapeutics, Inc.’s operating income has declined by 511.2% (from -$560.7 thousand to -$3.43 million).
- The most recent figure is from Inhibitor Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: